Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;5(4):458-462.
doi: 10.3892/mco.2016.978. Epub 2016 Aug 4.

Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma

Ana Cebollero  1 , Teresa Puértolas  1 , Isabel Pajares  1 , Lourdes Calera  1 , Antonio Antón  1
Affiliations

Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma

Ana Cebollero et al. Mol Clin Oncol. 2016 Oct.

Abstract

A retrospective observational study was conducted on patients diagnosed with serine/threonine-protein kinase B-Raf (BRAF)-mutated metastatic melanoma, who underwent first-line therapy with BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors (vemurafenib, dabrafenib or a combination of dabrafenib and trametinib) at the Miguel Servet University Hospital (Zaragoza, Spain) between November, 2011 and August, 2015. The aim of this study was to analyse the toxicity produced by BRAF and MEK inhibitors. The most common toxicities were similar to those published in clinical trials, particularly arthralgia, alopecia and photosensitivity in the vemurafenib group; asthenia, hyperkeratosis and dry skin in the dabrafenib group; and diarrhoea and dry skin in the dabrafenib plus trametinib group. Toxicities that had not been described in clinical trials were also identified. Thus, the present study confirmed that the results obtained in clinical trials are similar to those obtained in clinical practice.

Keywords: melanoma; serine/threonine-protein kinase B-Raf/mitogen-activated protein kinase kinase inhibitors; toxicity.

PubMed Disclaimer

References

    1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality un Europe in 2006. Ann Oncol. 2007;18:581–592. doi: 10.1093/annonc/mdl498. - DOI - PubMed
    1. Sáenz S, Conejo-Mir J, Cayuela A. Melanoma epidemiology in Spain. Actas Dermosifiliogr. 2005;96:411–418. doi: 10.1016/S0001-7310(05)73105-7. - DOI - PubMed
    1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–6206. doi: 10.1200/JCO.2009.23.4799. - DOI - PMC - PubMed
    1. Slingluff CI, Jr, Flaherty K, Rosenberg SA, et al. Cutaneous melanoma. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology. 9th edition. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011. pp. 1643–1691.
    1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American joint committe on cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634. - PubMed